Category: Bio & Healthcare

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics has resolved to convene its 15th Annual General Meeting of Shareholders on March 20 to vote on agenda items including financial statement approval, articles of incorporation amendments, and director appointments. 📊 [Key Disclosure Details & Financial Figures] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌…

Read More “[Disclosure] Samsung Biologics (207940) – Decision on Calling of General Shareholders Meeting / 2026-02-11” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary ALTEOGEN decided on a year-end cash dividend of KRW 371 per share for both common stock and preferred stock (RCPS) for FY2025. The total dividend payout amounts to approximately KRW 20.0B. 📊 [Key Disclosure Details & Major Figures Summary] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌…

Read More “[Disclosure] ALTEOGEN (196170) – Decision on Cash/In-Kind Dividend / 2026-02-11” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion is additionally listing 87,292 common shares on February 13, 2026, following the exercise of stock options by employees. 📊 [Key Disclosure Details & Financial Summary] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification of Additional Listing Execution on Scheduled Date (February 13, 2026) This disclosure…

Read More “[Disclosure] Celltrion (068270) – Additional Listing (Exercise of Stock Options) / 2026-02-10” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion has disclosed the previously withheld subject count (153 patients) for the Phase 3 clinical trial plan amendment application for CT-P55 (Cosentyx biosimilar candidate) in Europe through a corrective filing following regulatory approval. 📊 [Key Disclosure Details & Financial Summary] 📝 Editor’s Comment (Key Follow-up Checkpoint)…

Read More “[Disclosure] Celltrion (068270) – Application for Amendment of Phase 3 Clinical Trial Plan for CT-P55 in Europe (Correction) / 2026-02-10” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion has received final approval from the European Medicines Agency (EMA) for the amendment of the Phase 3 clinical trial plan (Part 1 & Part 2) for CT-P55 (Cosentyx biosimilar candidate). 📊 [Key Disclosure Details & Financial Summary] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification…

Read More “[Disclosure] Celltrion (068270) – Approval for Amendment of Phase 3 Clinical Trial Plan for CT-P55 (Cosentyx Biosimilar) in Europe (Part 1 & 2) / 2026-02-10” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion reported record-high annual revenue of KRW 4.16T (+17.01%) and operating profit of KRW 1.17T (+137.49%) on a consolidated basis for FY2025, driven by expanding high-margin product sales and post-merger cost stabilization. 📊 [Key Disclosure Details & Financial Summary] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌…

Read More “[Disclosure] Celltrion (068270) – Change in Sales or Loss Structure by More Than 30% (15% for Large Corporations) / 2026-02-05” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion reported provisional Q4 2025 consolidated revenue of KRW 1.33T (+25.06% YoY) and operating profit of KRW 475.2B (+141.94% YoY). 📊 [Key Disclosure Details & Financial Summary] [Q4 2025 Quarterly Financials (Unit: KRW Million)] [FY2025 Annual Cumulative Financials (Unit: KRW Million)] 📝 Editor’s Comment (Key Follow-up…

Read More “[Disclosure] Celltrion (068270) – Provisional Earnings Release (Consolidated Basis) / 2026-02-05” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary ALTEOGEN reported provisional separate financial results for FY2025, recording revenue of KRW 202.12B (+117.4% YoY) and operating profit of KRW 114.80B (+274.8% YoY). 📊 [Key Disclosure Details & Major Figures Summary] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification of Official Audit Report and Annual Report…

Read More “[Disclosure] ALTEOGEN (196170) – Provisional Financial Results / 2026-02-02” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion has decided to dispose of 11,379 common treasury shares (approx. KRW 1.65B) to grant shares following the exercise of stock options by 10 employees. 📊 [Key Disclosure Details & Financial Summary] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification of Treasury Share Delivery Completion and…

Read More “[Disclosure] Celltrion (068270) – Decision on Disposal of Treasury Shares / 2026-01-21” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics has officially disclosed its guidance for FY2026 consolidated revenue, targeting KRW 5.32T. 📊 [Key Disclosure Details & Financial Figures] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Tracking Actual FY2026 Revenue Performance Against Annual Guidance This disclosure provides the company’s FY2026 revenue guidance based on…

Read More “[Disclosure] Samsung Biologics (207940) – Forecast of Operating Performance (Fair Disclosure) / 2026-01-21” »